Glenmark Pharmaceuticals Ltd vs Jubilant Pharmova Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2034 as of 17 Feb 12:23 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 13 on March 2021 to 16.8 on March 2025 . This represents a CAGR of 5.26% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 10838 crore on March 2021 to ₹ 14220 crore on March 2025 . This represents a CAGR of 5.58% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The revenue of Jubilant Pharmova Ltd for the Dec '25 is ₹ 2143 crore as compare to the Sep '25 revenue of ₹ 1976 crore. This represent the growth of 8.44% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The ebitda of Jubilant Pharmova Ltd for the Dec '25 is ₹ 270.2 crore as compare to the Sep '25 ebitda of ₹ 345.3 crore. This represent the decline of -21.75% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The net profit of Jubilant Pharmova Ltd changed from ₹ 481.8 crore to ₹ 55.8 crore over 7 quarters. This represents a CAGR of -70.83% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 37.14 % on March 2021 to 414.06 % on March 2025 . This represents a CAGR of 61.97% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
Company name was changed to 'Jubliant Organosys Limited' in November, 2001 and was again changed to 'Jubilant Life Sciences Limited' in October, 2009 and further it attained a new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Jubilant Pharmova Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 67,519 Cr while Market cap of Jubilant Pharmova Ltd is 14,821 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

As of May 5, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2392.6. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹930.4.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.